Recon: Gilead claims remdesivir reduced mortality in Phase 3 study; FDA staff flag ocular toxicities ahead of GSK myeloma drug panel

• Special Report: How the Trump administration secured a secret supply of execution drugs (Reuters)
• Trump will sign three executive orders on lowering drug prices: chief of staff (Reuters)
• Gilead says remdesivir data show reduced risk of death (Financial Times) (Endpoints) (Reuters) (Press)
• FDA Says to Review Side Effect of GSK's Multiple Myeloma Drug (Reuters) (BioPharmaDive) (Endpoints)
• Blackstone hits $4.6B fundraising goal, teeing up big bets on late-phase R&D (Fierce) (Endpoints)
• Relay Therapeutics, focused on solid tumors, seeks to raise $250M in IPO (STAT)
• Despite the pandemic, prices for many drugs keep rising (STAT)

• German Biotech Sees Its Coronavirus Vaccine Ready for Approval by December (WSJ)
• Fujifilm's Avigan inconclusive in COVID-19 patients in Japan trial (Reuters)
• UK turns down EU coronavirus vaccine scheme (The Telegraph)
• NICE backing for Takeda's Adcetris for rare lymphoma (PharmaTimes)
• EU Pharmaceutical Strategy Roadmap Seen As Weak On Innovation (Pink Sheet)
• Australia approves Gilead's remdesivir for COVID-19 treatment (Reuters) (TGA)

• The Coronavirus Can Be Airborne Indoors, W.H.O. Says (NYTimes)
• Trump’s health officials find ways to contradict his message downplaying virus risks (Politico)
• These Scientists Raced to Find a Covid-19 Drug. Then the Virus Found Them. (NYTimes)
• Hepatitis C drugs help combat Covid-19 in trials (Financial Times)
• Fetal coronavirus infection is possible, small study suggests (NBC)
• Siemens COVID-19 antibody test beats rivals in head-to-head study (MedtechDive)
• Coronavirus (COVID-19) Update: Daily Roundup July 9, 2020 (FDA)

• FDA new drug approvals in Q2 2020 (Nature)
• EU Checks Pharma’s Appetite To Share Market Launch Intentions (Pink Sheet)
• GSK's Shingrix supply recovers thanks to drop in vaccinations, uninterrupted production (Fierce)
• Top biotech analyst projects a gloomy outlook for Pfizer's JAK portfolio (Endpoints)
• Ophthalmic drugs, cancer cell therapies attract $340M+ on two HKEX biotech debuts (Endpoints)
• Another four biotechs scratch out the first number and ask for more as IPO boom continues (Endpoints)
• Bayer's finerenone hits targets in diabetes/kidney disease trial (PharmaTimes)
• Allergan Declines To Confirm Abicipar Pegol Fate (Pink Sheet)
• UK’s CMA Issues Fines Over Fludrocortisone (Pink Sheet)
• Harbour BioMed nabs meaty C round as cancer, COVID-19 work draws investors (Fierce)
• AstraZeneca signs computational drug discovery collaboration; J&J-partnered Fate cleared for the clinic (Endpoints)
• Bob Goeltz bolts Unity Biotechnology to become CFO at Arcus Biosciences; John Johnson tapped for his latest CEO gig (Endpoints)
• A new venture fund amid a pandemic? In the Nordics? Eir Ventures brings it on with €76M first close (Endpoints)
• FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity (Press)

• EU Industry Wants IVDR Delay, Grace Period For More Products And Phased Implementation (MedtechInsight)
• Interim FDA-Mandated Postmarket Study Finds Essure Has Significantly Higher Rates Of Adverse Events (MedtechInsight)
• Malaysia's MDA publishes post-market surveillance guidance documents (Emergo)
• Spinal fixation system – risk of implant failure prior to completion of bone healing (MDA/2020/020) (MHRA)

• Office of Women's Health Strategic Priorities; Establishment of a Public Docket; Request for Comments (FDA)
• Meeting highlights from the Pharmacovigilance Risk Assessment Committee (EMA)
• Full Fed. Circ. Won't Consider Standing In Novartis Drug Case (Law360)
• Feds Indict 4 In Alleged $34M Pharma Kickback Scheme (Law360)
• 1st Circ. Affirms Pharmacists' Guilt In Meningitis Outbreak (Law360)
• NuVasive Spinal Fusion Patents Largely Survive PTAB Review (Law360)
• A Look At CMS' Proposed Medicaid Drug Rebate Changes (Law360)
• Father and Sons Charged in Miami Federal Court with Selling Toxic Bleach as Fake “Miracle” Cure for Covid-19 and Violating Court Orders (FDA)